A 4-week delay in cancer treatment can increase mortality across surgical, systemic treatment, and radiotherapy indications for seven cancers, with longer delays being more and more harmful to patients, suggest the results of a systematic review and meta-analysis.
Breast cancer patients face a high risk of skeletal-related events (SREs), particularly when diagnosed at advanced stages, reports a new Indonesia study presented at the recently concluded 2020 Asia Virtual Congress of the European Society of Medical Oncology (ESMO Asia 2020). Oncological and reproductive factors seem to affect this risk and may be worth monitoring for.
In a subgroup analysis of the phase IIIb CompLEEment-1 trial, ribociclib plus letrozole showed a manageable safety profile in Asian patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC).
While lung cancer is relatively rare among kidney transplant recipients, it remains a dangerous complication, carrying high rates of metastasis and mortality, according to a Philippine case series presented at the recently concluded 2020 Asia Virtual Congress of the European Society of Medical Oncology (ESMO Asia 2020)
The neratinib/capecitabine combination still confers survival advantage over lapatinib plus capecitabine in the subgroup of Asian patients with heavily treated HER2-positive metastatic breast cancer (MBC), according to an exploratory analysis of the phase III NALA trial.
Precision therapy for prostate cancer (PC) is becoming reality, with recent studies demonstrating efficacy of this approach in patients with metastatic castration-resistant PC (mCRPC) with certain DNA damage repair (DDR) alterations or PTEN loss.
Several markers of inflammation hold clue to identifying cancer patients at increased risk of death from COVID-19, according to data from OnCovid reported during the European Society for Medical Oncology (ESMO) Asia Virtual Congress.
Pathologic complete response (pCR) rates have significantly improved in patients with early-stage triple-negative breast cancer (TNBC) on neoadjuvant atezolizumab plus chemotherapy regardless of programmed death-ligand 1 (PD-L1) status, with an acceptable safety profile, relative to those on chemotherapy alone, results from the Impassion031 study have shown.
Asian breast cancer patients and caregivers place similar importance on the types of support they need at diagnosis, according to a Singapore study. Notably, patients place more value on family support, while caregivers regard prompt information and side effects at the time of diagnosis and early treatment to be extremely important.
Venetoclax in combination with bortezomib and dexamethasone significantly improved progression-free survival (PFS) and response rates in the BELLINI trial in patients with relapsed/refractory (R/R) multiple myeloma (MM), with even greater benefits seen in patients with t(11;14) translocation or high BCL2 gene expression.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.